Juan C. Duque

Juan C. Duque

Auto-generated profile, based on publicly available information

Juan C. Duque

Katz Family Division of Nephrology and Hypertension, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Clinical Nephrology
Verified
Journal Article
Closed access
JDJuan C. Duque
Juan C. Duque
ADAdriana Dejman
Adriana Dejman
VVVasuki Venkat
Vasuki Venkat
MHMaria Hernandez
Maria Hernandez
DRDavid Roth
David Roth
MLMarco A. Ladino
Marco A. Ladino
Hepatitis C virus (HCV) infection has been associated with several extrahepatic adverse clinical outcomes, including an accelerated rate of loss of kidney function in patients with chronic kidney disease (CKD) and an increased mortality in patients with CKD and kidney failure on hemodialysis. Clinical trials using direct-acting antiviral (DAA) agents have uniformly achieved sustained viral response at 12 weeks (SVR12) rates of > 90% in the general population as well as in patients with CKD/kidney failure on hemodialysis. Sofosbuvir is a DAA prodrug that is phosphorylated into the active metabolite GS-461203, with subsequent dephosphorylation into the inactive metabolite GS-331007. The kidneys clear both sofosbuvir and GS-331007, and its use has been associated with worsening kidney function in some studies. In the HCV-TARGET study, patients with an estimated glomerular filtration rate (eGFR) < 30 mL/min at the initiation of sofosbuvir-based therapy had higher rates of deterioration of kidney function compared to patients with higher eGFR [1]. However, based on recent data demonstrating safety in patients with advanced CKD, the US Food and Drug Administration (FDA) approved the use of sofosbuvir-containing regimens in patients with CKD 4/5 (eGFR of less than 30 mL/min/1.73m2) and end-stage renal disease (ESRD) in late 2019. The current report describes 8 HCV-infected patients who developed acute kidney injury (AKI) with biopsy-proven acute interstitial nephritis (AIN) temporally associated with the use of DAAs. The mean age of the group was 61.3 (± 6 years). The most common HCV genotype (GT) was 1a (n = 7). The DAA formulations were sofosbuvir/ledipasvir (n = 5), elbasvir/grazoprevir (n = 2), and sofosbuvir/simeprevir (n = 1). All patients achieved an SVR12. The mean serum creatinine at the initiation of DAA treatment was 1.5 mg/dL (± 0.6) and increased to 2.03 mg/dL (± 0.7) by the last day of DAA administration. The kidney biopsies were performed at a mean of 320 days (± 247) after achieving an SVR12, at which point the mean creatinine had increased to 2.3 mg/dL (± 1.4). All patients received a course of high-dose corticosteroids after the diagnosis of AIN was confirmed by biopsy. Serum creatinine levels at 3 and 6 months following the completion of steroid therapy were 2.8 (± 1.2) and 3.1 mg/dL (± 1.5), respectively. Three patients had worsening CKD and progressed to kidney failure requiring hemodialysis. These results are consistent with earlier studies demonstrating the efficacy of the DAAs in HCV-infected CKD patients. Of note, the demonstration of AIN in these patients may explain some of the AKI events reported with the use of DAAs in patients with CKD.

1 April 2018 in Surgery
Verified
Journal Article
Closed access
DHDiana R. Hernandez
Diana R. Hernandez
AAAdriana Artiles
Adriana Artiles
JDJuan C. Duque
Juan C. Duque
LMLaisel Martinez
Laisel Martinez
MPMariana T. Pinto
Mariana T. Pinto
RLRoberta Lassance-Soares
Roberta Lassance-Soares

1 January 2024 in Korean Circulation Journal
Verified
Journal Article
Open access
PDF file
NFNicole Felix
Nicole Felix
MGMateus M. Gauza
Mateus M. Gauza
LTLarissa Teixeira
Larissa Teixeira
MGMaria Eduarda S. Guisso
Maria Eduarda S. Guisso
ANAlleh Nogueira
Alleh Nogueira
RCRhanderson Cardoso
Rhanderson Cardoso
Felix N, et al. Korean Circ J. 2024 Apr;54:e46. https://doi.org/10.4070/kcj.2023.0241

1 January 2022 in Clinical Nephrology – Case Studies
Verified
Journal Article
Open access
JDJuan C. Duque
Juan C. Duque
MTMarwan Tabbara
Marwan Tabbara
LMLaisel Martinez
Laisel Martinez
KMKaren Manzur-Pineda
Karen Manzur-Pineda
RVRoberto I. Vazquez-Padron
Roberto I. Vazquez-Padron
ADAdriana Dejman
Adriana Dejman
Endovascular stent fractures are commonly seen in arteries but are rare events in the venous system. Stents deployed in hemodialysis vascular accesses can fracture and migrate to proximal locations. Complications associated with stent fracture include in-stent stenosis and central vein stenosis. In this report, we present a unique case of a hemodialysis access stent fracture that migrated to the left ventricle and manifested with chest pain.

1 November 2022 in Clinical Nephrology
Verified
Journal Article
Open access
KMKaren Manzur-Pineda
Karen Manzur-Pineda
LMLaisel Martinez
Laisel Martinez
RARoger Alvarez
Roger Alvarez
ADAdriana Dejman
Adriana Dejman
RVRoberto I. Vazquez-Padron
Roberto I. Vazquez-Padron
JDJuan C. Duque
Juan C. Duque
Background: Pulmonary hyper-tension (PH) is common in end-stage renal disease (ESRD) patients and is associated with increased all-cause and cardiovascular mortality in this group. There is scarce data on the long-term effect of arteriovenous fistula (AVF) creation on pulmonary hypertension (PH) and the reflected changes in echocardiographic measurements. Materials and methods: This is a retrospective study of 54 patients who underwent AVF creation be-tween 2009 and 2014 and with echocardiographic evaluations before and after surgery. We analyzed pairwise changes in right ventricular systolic pressure (RVSP), right atrial pressure (RAP) during systole, left ventricular mass (LVM), tricuspid regurgitation (TR), mitral E/E' ratio, and ejection fraction (EF), as well as the factors that predicted change in RVSP after surgery. Results: The median time for the preoperative echocardiogram was 0.3 years (interquartile range (IQR) 0.2 - 0.7 years) prior to AVF creation, while the follow-up echo was done 1.3 (0.6 - 2.1) years after surgery. 67% of the patients had RVSP > 37 mmHg at baseline. There was a significant reduction in RVSP after AVF creation compared to baseline (median 33 (IQR 26 - 43) vs. 46 mmHg, p = 0.0015), with 59% of the patients experiencing a decrease and 19% remaining stable. There were also significant decreases in LVM (201 (143 - 256) vs. 215 (163 - 276), p = 0.045) and RAP sys-tole (10 (10 - 15) vs. 3 (3 - 8); p < 0.001) after surgery. Higher preoperative weight (p = 0.038) and RVSP (p = 0.006), and use of loop diuretics (p = 0.015) were significantly associated with improvement in RVSP after AVF creation. Conclusion: Our results suggest that AVF creation is associated with a significant reduction or stable measurements of RVSP in the ESRD population, likely due to an improvement in volume status.

3 May 2025 in The Journal of Vascular Access
Verified
Journal Article
Closed access
CMChristopher Montoya
Christopher Montoya
DRDaniel Del Castillo Rix
Daniel Del Castillo Rix
CPCamilo Polania-Sandoval
Camilo Polania-Sandoval
LMLaisel Martinez
Laisel Martinez
ADAdriana Dejman
Adriana Dejman
JDJuan C Duque
Juan C Duque
Introduction: Hypertension (HTN) is highly prevalent among patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD), uncontrolled HTN as well as high blood pressure variability (BPV) can significantly impact cardiovascular health. This study aims to understand the impact of BPV in patients with ESKD following arteriovenous fistula (AVF) creation for hemodialysis, to better understand its association with age, sex, BMI, and cardiovascular risk. Methods: A retrospective analysis was conducted on 83 patients who underwent AVF creation between February 2019 and October 2020 at University of Miami Hospital. During 20 months, blood pressure measurements were collected from medical records at four different times during AVF access creation process, and BPV was quantified using machine learning clustering techniques. Results: The study identified three distinct clusters among the 83 patients with ESKD who underwent AVF creation. Cluster 1 ( n = 28) was characterized by high blood pressure variability, with a mean systolic blood pressure standard deviation of 16.2 mmHg. This cluster exhibited a significantly higher cardiovascular risk rate of 42.9% compared to Cluster 2 ( n = 30) and Cluster 3 ( n = 25), which had lower variability with mean systolic blood pressure standard deviations of 10.3 and 8.7 mmHg, respectively, and cardiovascular risk rates of 16.7% and 12.0%. Age, sex, and BMI did not differ significantly across the clusters. Conclusion: This study underscores the association between blood pressure variability and the increased risk of cardiovascular events, including myocardial infraction, stroke or heart failure in patients with ESKD undergoing AVF creation. Our findings highlight the critical need for vigilant monitoring of blood pressure fluctuations in this population and demonstrate how these variations are influenced by individual demographic factors. Further research is needed to develop targeted interventions to mitigate this risk.